AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31375619 — intervention group
Group type: EXPERIMENTAL
Intervention: pGMT
Number of subjects: 80
Study 30672178 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife therapy combined with moxa stick pressure moxibustion
Number of subjects: 60
Study 30672178 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (12 mg of betahistine mesylate, twice a day, and 75 mg of diclofenac sodium once daily)
Number of subjects: 60
Study 27377821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongenital tender point tenderness examination
Number of subjects: 92
Study 27377821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia (diagnosed by tender point tenderness)
Number of subjects: 92
Study 24150782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation (45 billion CFU of Lactobacillus, Bifidobacterium and Streptococcus strains)
Number of subjects: 10
Study 24150782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24150782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 10
Study 22386383 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with concurrent phlebectomies
Number of subjects: 100
Study 22386383 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound‐guided foam sclerotherapy (UGFS)
Number of subjects: 100
Study 18647300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 2614
Study 18647300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 2614
Study 18647300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614
Study 18647300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg and 60 mg combined)
Number of subjects: 2614
Study 16949445 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field end points
Number of subjects: 152
Study 16949445 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic disc end points
Number of subjects: 152
Study 12589283 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Gel (Karigel‐N, 5,000 ppm for 4 minutes daily)
Number of subjects: 80
Study 12589283 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Varnish (Duraflor, 22,600 ppm weekly)
Number of subjects: 80
Study 12589283 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Gel (Karigel‐N for 4 minutes weekly)
Number of subjects: 80
Study 12589283 — intervention group
Group type: COMPARATOR
Intervention: Control (washed with deionized/distilled water)
Number of subjects: 80
Study 10794478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 300 mg/day
Number of subjects: 27
Study 10794478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9532631 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoured wavers made from flour and water
Number of subjects: 100
Study 9532631 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional testing
Number of subjects: 100
Study 9532631 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole mouth testing
Number of subjects: 100
Study 9532631 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavers
Number of subjects: 100
Study 8468768 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) at levels of 0, 2, 4, 5, 6, 8, 10, 12, 14, 15, and 20 cm H2O
Number of subjects: 10
Study 3520177 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized feedback on prescription charges
Number of subjects: 0
Study 3520177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29485525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) program for 3 months
Number of subjects: 40
Study 29485525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PR program)
Number of subjects: 40
Study 27469242 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 31
Study 27469242 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31
Study 24262772 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 923
Study 24262772 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper Questionnaire (PQ)
Number of subjects: 923
Study 24262772 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 923
Study 24262772 — intervention group
Group type: COMPARATOR
Intervention: Personal Computer (PC)
Number of subjects: 923
Study 22536592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene gel
Number of subjects: 110
Study 22536592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 19886920 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (AIT) - Graza (Phleum pratense 75,000 SQ‐T/2800 BAU; ALK, Denmark) for 3 years followed by 1 year follow-up
Number of subjects: 283
Study 19886920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 19886920 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (AIT) - Graza
Number of subjects: 283
Study 18165645 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy plus Adjuvant Radiation Therapy (RP+RT)
Number of subjects: 217
Study 18165645 — intervention group
Group type: COMPARATOR
Intervention: Radical Prostatectomy alone (RP)
Number of subjects: 217
Study 17998695 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Number of subjects: 0
Study 17998695 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant setting trials
Number of subjects: 0
Study 17998695 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 12951650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 IU, once daily)
Number of subjects: 20
Study 12951650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10731776 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective pictures (pleasant and unpleasant) presented in a random order with a faster presentation rate (1.5 s)
Number of subjects: 0
Study 10731776 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective pictures of high arousal
Number of subjects: 0
Study 10731776 — intervention group
Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 0
Study 8964890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg DEX daily
Number of subjects: 25
Study 8964890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1390330 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean daily dosage 56 +/- 5 mg)
Number of subjects: 29
Study 1390330 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dosage 9.5 +/- 0.4 mg)
Number of subjects: 29
Study 3924981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonic acid cream applied three times a day for 5 days
Number of subjects: 68
Study 30275428 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program with Spirulina maxima (SE)
Number of subjects: 52
Study 30275428 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program without Spirulina maxima (Ex)
Number of subjects: 52
Study 30275428 — intervention group
Group type: EXPERIMENTAL
Intervention: No-exercise program with Spirulina maxima (Sm)
Number of subjects: 52
Study 30275428 — intervention group
Group type: COMPARATOR
Intervention: No-exercise program without Spirulina maxima (C)
Number of subjects: 52
Study 28264725 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) using PiezoWave 2 shockwave system, administered three times per week for 3 weeks.
Number of subjects: 0
Study 28264725 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment to the calf muscle bulk, administered three times per week for 3 weeks.
Number of subjects: 0
Study 25243340 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-101 (12.5-400 μg)
Number of subjects: 42
Study 25243340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24257398 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block (CISB) with 20 mL of 0.5% ropivacaine as a bolus and infusion of 0.2% ropivacaine at 5 mL/h for 48 hours
Number of subjects: 71
Study 24257398 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection interscalene block (SISB) with 20 mL of 0.5% ropivacaine
Number of subjects: 71
Study 24257398 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 71
Study 20920825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 18491170 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT performed before discharge
Number of subjects: 96
Study 18491170 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT performed 3 months after discharge
Number of subjects: 96
Study 18491170 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 96
Study 16126809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (800 mg/day for 4 weeks)
Number of subjects: 32
Study 16126809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12545257 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine sulfate
Number of subjects: 113
Study 12545257 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.25% ropivacaine
Number of subjects: 113
Study 12545257 — intervention group
Group type: COMPARATOR
Intervention: Physiological NaCl solution (placebo)
Number of subjects: 113
Study 10691067 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmarch bandage
Number of subjects: 0
Study 10691067 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm elevation/arterial compression (AE/AC)
Number of subjects: 0
Study 10691067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic vinyl splint
Number of subjects: 0
Study 9506001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine HCl (4.4 mg every 12 hrs)
Number of subjects: 12
Study 9506001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine with ketoconazole (200 mg every 12 hrs)
Number of subjects: 12
Study 9506001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole alone (after a 21-day washout period)
Number of subjects: 12
Study 9506001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the azelastine/placebo group)
Number of subjects: 12
Study 8476215 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 intracutaneous injection
Number of subjects: 0
Study 3533699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.5-4 mg/day)
Number of subjects: 24
Study 3533699 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 24
Study 3533699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 24
Study 30126672 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) + Desmopressin (40 micrograms, 4 puffs)
Number of subjects: 124
Study 30126672 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg) + Placebo
Number of subjects: 124
Study 27890487 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol intake (upper tertile)
Number of subjects: 2573
Study 27890487 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol intake (lower tertile)
Number of subjects: 2573
Study 25343570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion suctioning
Number of subjects: 352
Study 25343570 — intervention group
Group type: COMPARATOR
Intervention: No subglottic secretion suctioning (control)
Number of subjects: 352
Study 23290819 — intervention group
Group type: EXPERIMENTAL
Intervention: PPM plus cisplatin (230 mg/m(2) + 60 mg/m(2))
Number of subjects: 276
Study 23290819 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (175 mg/m(2) + 60 mg/m(2))
Number of subjects: 276
Study 21069291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days urinary catheterization
Number of subjects: 90
Study 21069291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days urinary catheterization
Number of subjects: 90
Study 21069291 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days urinary catheterization
Number of subjects: 90
Study 19920718 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS/TENS
Number of subjects: 8
Study 19920718 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 8
Study 19920718 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 8
Study 19920718 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS/TENS vs tDCS
Number of subjects: 8
Study 16989957 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 0
Study 16989957 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 14755810 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 910
Study 14755810 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 910
Study 11207081 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients with left ventricular ejection fraction <25%
Number of subjects: 9
Study 11207081 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients with left ventricular ejection fraction <25%
Number of subjects: 9
Study 11207081 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 9
Study 11207081 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 9
Study 11207081 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 9
Study 9633342 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring during weaning from mechanical ventilation
Number of subjects: 0
Study 7877883 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated cystinotic children (n=9)
Number of subjects: 9
Study 7877883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystinotic children treated with cysteamine
Number of subjects: 9
Study 7877883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystinotic children after abrogation of cysteamine treatment for 3 or 4 days
Number of subjects: 9
Study 7877883 — intervention group
Group type: COMPARATOR
Intervention: Control children (n=8)
Number of subjects: 9
Study 7877883 — intervention group
Group type: COMPARATOR
Intervention: Normal adults (n=25)
Number of subjects: 9
Study 3278170 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid
Number of subjects: 60
Study 3278170 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 29851267 — intervention group
Group type: EXPERIMENTAL
Intervention: ANACONDA with simple presetting parameters
Number of subjects: 10
Study 29851267 — intervention group
Group type: EXPERIMENTAL
Intervention: ANACONDA with detailed presetting parameters
Number of subjects: 10
Study 29851267 — intervention group
Group type: EXPERIMENTAL
Intervention: MORFEUS with simple presetting parameters
Number of subjects: 10
Study 29851267 — intervention group
Group type: EXPERIMENTAL
Intervention: MORFEUS with detailed presetting parameters
Number of subjects: 10
Study 28455473 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKA
Number of subjects: 60
Study 28455473 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned TKA
Number of subjects: 60
Study 26113503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant in cataract after implant (CAI) group
Number of subjects: 0
Study 26113503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant in cataract before implant (CBI) group
Number of subjects: 0
Study 26113503 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant
Number of subjects: 0
Study 23123504 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (10 rpm)
Number of subjects: 8
Study 23123504 — intervention group
Group type: COMPARATOR
Intervention: HIGH (50 rpm)
Number of subjects: 8
Study 21113799 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of co-morbid drug abuse
Number of subjects: 0
Study 21113799 — intervention group
Group type: EXPERIMENTAL
Intervention: Past adolescent conduct disorder, being younger and male, symptoms of Akathisia, and drug abuse
Number of subjects: 0
Study 18664707 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Identification (WI)
Number of subjects: 0
Study 18664707 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude Estimation Scaling (MES)
Number of subjects: 0
Study 18664707 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Identification (WI) and Magnitude Estimation Scaling (MES)
Number of subjects: 0
Study 16556697 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone ventilation for 20 h/d
Number of subjects: 136
Study 16556697 — intervention group
Group type: COMPARATOR
Intervention: Supine ventilation
Number of subjects: 136
Study 12728089 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate (45 mg/kg/d) for 7 days
Number of subjects: 66
Study 12728089 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 66
Study 11085693 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 22
Study 8976822 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 500 mg/m2 plus two doses of amifostine 910 mg/m2/dose
Number of subjects: 0
Study 8976822 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 500 mg/m2
Number of subjects: 0
Study 1546776 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education
Number of subjects: 313
Study 1546776 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education with optional HIV antibody testing
Number of subjects: 313
Study 1546776 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 313
Study 6208387 — intervention group
Group type: EXPERIMENTAL
Intervention: D-40 (5 units administered at 75 to 100 ml/hr, two during and immediately after operation, one each 3 days postoperatively)
Number of subjects: 156
Study 6208387 — intervention group
Group type: COMPARATOR
Intervention: Control (no D-40 administered)
Number of subjects: 156
Study 6208387 — intervention group
Group type: EXPERIMENTAL
Intervention: D-40
Number of subjects: 156
Study 6208387 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study 27381981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouncer friendliness (unfriendly)
Number of subjects: 681
Study 27381981 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature (hot)
Number of subjects: 681
Study 27381981 — intervention group
Group type: EXPERIMENTAL
Intervention: Patron sex composition (majority male)
Number of subjects: 681
Study 27381981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fight participants
Number of subjects: 681
Study 27381981 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 681
Study 30285894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 24
Study 30285894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26724311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including direct mailers, phone calls, in-person meetings, and hiring community members
Number of subjects: 31
Study 25306750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day in combination with metformin 2 g/day
Number of subjects: 82
Study 25306750 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1.5-2 g/day
Number of subjects: 82
Study 19640353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 600 - 6,000 microg
Number of subjects: 16
Study 19640353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15805377 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 0.01 mg/kg administered intravenously before oral administration of 1 mL of 30% glucose
Number of subjects: 30
Study 15805377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution) administered intravenously before oral administration of glucose
Number of subjects: 30
Study 11207036 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 intratumoral injection (10 KE) before surgery
Number of subjects: 370
Study 11207036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OK-432 injection)
Number of subjects: 370
Study 9562618 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin during hemodialysis
Number of subjects: 0
Study 9562618 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of heparin in normal controls
Number of subjects: 0
Study 8056701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily i.v.
Number of subjects: 126
Study 8056701 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg once daily i.v.
Number of subjects: 126
Study 8056701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily i.v. (treated > or = 48 hours)
Number of subjects: 126
Study 8056701 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg once daily i.v. (treated > or = 48 hours)
Number of subjects: 126
Study 8056701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and Netilmicin
Number of subjects: 126
Study 2973215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LV hypertrophy
Number of subjects: 544
Study 2973215 — intervention group
Group type: COMPARATOR
Intervention: Patients without LV hypertrophy
Number of subjects: 544
Study 12500513 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue 0.5 mg.kg‐1.h‐1
Number of subjects: 30
Study 12500513 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 30
Study 30502851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM) - 1000mg IV infusion over 15 minutes
Number of subjects: 246
Study 30502851 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron Polymaltose (IPM) - 1000mg IV infusion over 2 hours
Number of subjects: 246
Study 30502851 — intervention group
Group type: COMPARATOR
Intervention: Oral Ferrous Sulphate - 325mg daily until delivery
Number of subjects: 246